Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10540885 | 0.80 | CHRNA7 (0.64) | CHRNA7 | |
| SCHEMBL7955416 | 0.76 | GAA (0.64) | — | |
| SCHEMBL4959081 | 0.75 | CHRNA7 (0.55) | CHRNA7HTR3A | |
| SCHEMBL2228215 | 0.74 | CHRNA7 (0.64) | CHRNA7HTR3A | |
| SCHEMBL2228214 | 0.74 | CHRNA7 (0.64) | CHRNA7HTR3A | |
| SCHEMBL7281094 | 0.74 | CHRNA7 (0.64) | CHRNA7HTR3A | |
| SCHEMBL3928547 | 0.74 | CHRNA7 (0.59) | CHRNA7HTR3A | |
| SCHEMBL13444722 | 0.74 | CHRNA7 (0.59) | CHRNA7HTR3A | |
| SCHEMBL4961084 | 0.74 | HTR3A (0.56) | CHRNA7HTR3A | |
| SCHEMBL9597487 | 0.72 | CHRNA7 (0.67) | CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558610-B1 | SUBSTITUTED AMINOQUINUCLIDINE COMPOUNDS AND THEIR USE AS DELTA-OPIOID RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-7179818-B2 | Substituted aminoquinuclidine compounds | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1558610-A2 | SUBSTITUTED AMINOQUINUCLIDINE COMPOUNDS AND THEIR USE AS DELTA-OPIOID RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040110789-A1 | Substituted aminoquinuclidine compounds | BOYD ROBERT E (US) | 2004-06-10 | — | — | US | disclosed |
| WO-2004035574-A2 | SUBSTITUTED AMINOQUINUCLIDINE COMPOUNDS AND THEIR USE AS DELTA-OPIOID RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110789-A1 | Substituted aminoquinuclidine compounds | OPRD1, OPRK1, OPRM1 | CHRNA7 104/4885HTR3A 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.